Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. (Q34639998)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Richard A. Larson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Andreas Hochhaus

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Giuseppe Saglio

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

10

object named as

T P Hughes

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

F J Giles

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

P D le Coutre

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J Pinilla-Ibarz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

N Gattermann

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J P Radich

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

G Martinelli

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

D-W Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

S Novick

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

K Gillis

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

X Fan

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J Cortes

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M Baccarani

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

H M Kantarjian

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

5 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

107-112

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

21 January 2018

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

7 January 2021

based on heuristic

inferred from DOI database lookup

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.181

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.181

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22763385%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34639998&oldid=2196904159"